HT, B.Braun partner to launch Adenocaine Hiberplegia syringe pump delivery system

Hibernation Therapeutics USA, LLC (HT) has partnered with B. Braun Medical Inc. (B.Braun) to introduce an innovative, low-cost syringe pump delivery system for the administration of its patented Adenocaine® Hiberplegia™ solution, the world's first non-depolarizing cardioplegia.

“and we are collecting additional data to better understand the clinical benefit of the Adenocaine® cardioplegia.”

For the first time, cardiac surgeons at The University of Kansas Hospital (KUMED), Kansas City, KS, USA successfully administered Adenocaine® Hiberplegia™ solution using the B.Braun Perfusor® Space syringe pump to aid in the arrest and protection of the heart during open heart surgery. "In our initial clinical cases, we have observed improved cardioprotection in some very difficult cases," stated Gregory F. Muehlebach, MD at KUMED, "and we are collecting additional data to better understand the clinical benefit of the Adenocaine® cardioplegia."

Adenocaine®'s polarizing patented formulation has shown superior myocardial protection and improved outcomes in preclinical studies and physicians are observing similar results during clinical use, in comparison to standard high potassium depolarizing cardioplegia. According to HT's CSO and James Cook University Professor Geoffrey P. Dobson: "The Adenocaine® technology places the heart in a more 'natural' state of suspended animation similar to that of a hibernating animal, making cardiac surgery safer for the patient, more predictable for the surgeon and economically compelling for hospitals and other purchasers of health care."

"By incorporating the B.Braun Perfusor® Space pump with its custom Adenocaine® drug library, clinicians can easily integrate the delivery of Adenocaine® into any existing cardioplegia delivery system and at any blood:cardioplegia ratio the perfusionist prefers," said David C. Field, CEO for HT. "This user-friendly, cost-effective syringe pump delivery system now makes the Adenocaine® solution available and affordable to any hospital."

Source:

Hibernation Therapeutics

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    B. Braun Melsungen AG. (2019, June 17). HT, B.Braun partner to launch Adenocaine Hiberplegia syringe pump delivery system. News-Medical. Retrieved on July 17, 2019 from https://www.news-medical.net/news/20110801/HT-BBraun-partner-to-launch-Adenocaine-Hiberplegia-syringe-pump-delivery-system.aspx.

  • MLA

    B. Braun Melsungen AG. "HT, B.Braun partner to launch Adenocaine Hiberplegia syringe pump delivery system". News-Medical. 17 July 2019. <https://www.news-medical.net/news/20110801/HT-BBraun-partner-to-launch-Adenocaine-Hiberplegia-syringe-pump-delivery-system.aspx>.

  • Chicago

    B. Braun Melsungen AG. "HT, B.Braun partner to launch Adenocaine Hiberplegia syringe pump delivery system". News-Medical. https://www.news-medical.net/news/20110801/HT-BBraun-partner-to-launch-Adenocaine-Hiberplegia-syringe-pump-delivery-system.aspx. (accessed July 17, 2019).

  • Harvard

    B. Braun Melsungen AG. 2019. HT, B.Braun partner to launch Adenocaine Hiberplegia syringe pump delivery system. News-Medical, viewed 17 July 2019, https://www.news-medical.net/news/20110801/HT-BBraun-partner-to-launch-Adenocaine-Hiberplegia-syringe-pump-delivery-system.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
B. Braun receives FDA approval to use 1g and 2g Ceftazidime in DUPLEX Drug Delivery System